** Shares of gene therapy developer Neurogene NGNE.O down 4.6% post-market to $30 as it seeks equity raise

** Neurological diseases-focused NGNE commences offering of stock and pre-funded warrants; deal size not disclosed

** Co intends to use net offering proceeds to fund clinical development of NGN-401, pre-commercial activities for NGN-401, and for working capital and other purposes

** Leerink, Stifel, Guggenheim, LifeSci Capital and William Blair joint bookrunners

** NGNE has ~15.8 mln shares outstanding for about $500 mln market cap

** Stock closed down 2.6% at $31.45 on Tues, trimming YTD gain to ~53%

** All 9 analysts covering the stock are bullish including 4 "strong buy" ratings; median PT $69, per LSEG data